Amy Sullivan
Finanzdirektor/CFO bei IO BIOTECH, INC.
Vermögen: 107 854 $ am 30.04.2024
Profil
Amy B.
Sullivan is currently the Chief Financial Officer at IO Biotech, Inc. She previously worked as the Head of Corporate Communications and Investor Relations at Genencor International, Inc., Idenix Pharmaceuticals LLC, and AMAG Pharmaceuticals, Inc. She also served as the VP of Strategic Operations and Corporate Affairs at Keryx Biopharmaceuticals, Inc. and as the Senior Vice President of Corporate Affairs at Kiadis Pharma NV.
Sullivan holds a Master's in Business Administration from Bentley University and an undergraduate degree from Salem International University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IO BIOTECH, INC.
0,11% | 15.03.2024 | 74 382 ( 0,11% ) | 107 854 $ | 30.04.2024 |
Aktive Positionen von Amy Sullivan
| Unternehmen | Position | Beginn |
|---|---|---|
| IO BIOTECH, INC. | Finanzdirektor/CFO | 15.10.2022 |
Ehemalige bekannte Positionen von Amy Sullivan
| Unternehmen | Position | Ende |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Public Communications Contact | - |
Genencor International, Inc.
 Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Investor Relations Kontakt | - |
| IDENIX PHARMACEUTICALS INC | Investor Relations Kontakt | - |
| KIADIS PHARMA N.V. | Investor Relations Kontakt | - |
| AMAG PHARMACEUTICALS, INC. | Investor Relations Kontakt | - |
Ausbildung von Amy Sullivan
| Bentley University | Masters Business Admin |
| Salem International University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IO BIOTECH, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
